<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00976404</url>
  </required_header>
  <id_info>
    <org_study_id>EraMune02</org_study_id>
    <nct_id>NCT00976404</nct_id>
  </id_info>
  <brief_title>Therapeutic Intensification Plus Immunomodulation to Decrease the HIV-1 Viral Reservoir</brief_title>
  <acronym>EraMune02</acronym>
  <official_title>Multicenter, Randomized, Non-comparative, Controlled Study of Therapeutic Intensification Plus Immunomodulation in HIV-infected Patients With Long-term Viral Suppression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Robert L. Murphy</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Objectif Recherche Vaccins SIDA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to discover a new approach in which human immunodeficiency
      virus (HIV) can be eradicated from an infected individual by intensified antiretroviral
      treatment coupled with immunomodulation. The hypothesis is that eradication is possible only
      if very potent antiretroviral drugs are delivered in conjunction with an immunomodulatory
      agent that simultaneously attack the viral reservoirs.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this study is to measure the impact of immunomodulation plus treatment
      intensification on the HIV reservoir in HIV-infected patients who have viral suppression on
      combination antiretroviral therapy. Treatment regimens first will be intensified by the
      addition of raltegravir and maraviroc for 8 week followed by immunomodulation with the NIH
      HIV-rAd5 vaccine plus DNA prime-boost for 24 weeks. The primary endpoint is measurement of
      change in peripheral cellular HIV DNA. A decrease of 0.5 log is considered significant. A
      secondary endpoints include change in HIV DNA in the rectal mucosa, immunologic changes in
      the peripheral blood and safety.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in HIV DNA in PBMCs at Week 56</measure>
    <time_frame>56 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in HIV DNA in Rectal Tissue at Week 56</measure>
    <time_frame>Week 56</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in CD4+ T Cell Count at Week 56</measure>
    <time_frame>Week 56</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HIV Specific T-cell Response to Env</measure>
    <time_frame>36 weeks</time_frame>
    <description>HIV-specific immunity: Interferon gamma ELISpot response to Env (clades A) at week 36 (one month after rAd5 boosting)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious Adverse Events Attributed to Study Treatments</measure>
    <time_frame>56 weeks</time_frame>
    <description>Grade 3 or 4 serious adverse events related to study treatments (raltegravir, maraviroc, or HIV-recombinant Ad5-based vaccine)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>HIV Infection</condition>
  <arm_group>
    <arm_group_label>Maraviroc + raltegravir intensification</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ART Intensification (addition of raltegravir and maraviroc to suppressive ART for 56 weeks)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Maraviroc + raltegravir intens. plus DNA + HIV-rAd5 vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ART Intensification (addition of raltegravir and maraviroc for 56 weeks) PLUS immunomodulation therapy with DNA prime vaccine (Weeks 8,12,16) + HIV-recombinant Ad5-based vaccine (Week 32)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DNA + HIV-rAd5 vaccine</intervention_name>
    <description>4 mg subcutaneous injection at weeks 8 (DNA prime), 12 (DNA prime), 16 (DNA prime), and 32 (HIV-rAd5)</description>
    <arm_group_label>Maraviroc + raltegravir intens. plus DNA + HIV-rAd5 vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ART intensification (raltegravir)</intervention_name>
    <description>raltegravir 400 mg PO BID for 56 weeks</description>
    <arm_group_label>Maraviroc + raltegravir intensification</arm_group_label>
    <arm_group_label>Maraviroc + raltegravir intens. plus DNA + HIV-rAd5 vaccine</arm_group_label>
    <other_name>Isentress</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ART intensification (maraviroc)</intervention_name>
    <description>maraviroc 150, 300, or 600 mg PO BID (depending on PK interactions with other medications) for 56 weeks</description>
    <arm_group_label>Maraviroc + raltegravir intensification</arm_group_label>
    <arm_group_label>Maraviroc + raltegravir intens. plus DNA + HIV-rAd5 vaccine</arm_group_label>
    <other_name>Selzentry</other_name>
    <other_name>Celsentri</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV-1 infection

          -  At least 3 years of ART without interruption (less than one month cumulative)

          -  ART regimen unchanged in the 3 months prior to screening

          -  One HIV plasma viral load (RNA) documented at least 3 years prior to entry, and at
             least 2 HIV plasma viral load (RNA) documented per year thereafter

          -  HIV plasma viral load (RNA) ≤ 500 copies/mL at least 3 years prior to entry, and HIV
             plasma viral load &lt; 500 copies/mL for &gt;90% of the measures thereafter

          -  HIV plasma viral load (RNA) below the limit of detection for all values within the
             past year (one virologic blip allowed)

          -  HIV plasma viral load below the limit of detection within 60 days of entry

          -  CD4+ count ≥ 350 cells/mm3 within 60 days of entry

          -  Proviral DNA ≥10 and ≤1000 copies/106 PBMCs within 75 days of entry

          -  Adeno5 neutralizing antibody titers of 250 or less within 75 days of entry

          -  Hemoglobin ≥ 10 g/dL within 60 days of entry

          -  Platelets ≥ 100,000 per microliter within 60 days of entry

          -  Hepatic transaminases (ALT and AST) ≤ 2.5 x ULN within 60 days of entry

          -  Creatinine clearance &gt; 50 mL/min by the Cockcroft-Gault equation within 60 days of
             entry

        Exclusion Criteria:

          -  Sexually active men and women who will not practice at least one form of barrier birth
             control (male partner using condoms, female partner using condoms, other barrier
             contraception, etc)

          -  Pregnancy

          -  Inability or unwillingness to provide informed consent

          -  HBsAg positive

          -  HCV antibody positive or HCV RNA detectable

          -  Previous use of an integrase inhibitor (ie raltegravir) or a CCR5 inhibitor (ie
             maraviroc, vicriviroc). Use of raltegravir for non-treatment failure indications such
             as intensification or toxicity switches is allowed.

          -  Immunologic therapeutic intervention (e.g. IL-2) within the past year

          -  Participation in another clinical drug or device trial where the last dose of drug was
             within the past 30 days or an investigational medical device is currently implanted

          -  Diagnosis of cancer within the last 5 years (except basal cell cutaneous cancers and
             cutaneous KS not requiring systemic therapy)

          -  Co-morbid condition with an expected survival of less than 12 months

          -  History of hypersensitivity to vaccination

          -  History of autoimmune disease, such as systemic lupus erythematosis (SLE) or
             Hashimoto's thyroiditis

          -  Active drug or alcohol use or dependence that, in the opinion of the site
             investigator, would interfere with adherence to study requirements
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Murphy, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cornell University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 9, 2009</study_first_submitted>
  <study_first_submitted_qc>September 11, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2009</study_first_posted>
  <results_first_submitted>September 4, 2014</results_first_submitted>
  <results_first_submitted_qc>September 10, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 12, 2014</results_first_posted>
  <last_update_submitted>September 10, 2014</last_update_submitted>
  <last_update_submitted_qc>September 10, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 12, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Northwestern University</investigator_affiliation>
    <investigator_full_name>Robert L. Murphy</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>HIV-1 infection</keyword>
  <keyword>Treatment intensification</keyword>
  <keyword>Immunomodulation</keyword>
  <keyword>HIV-rAd5 vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Raltegravir Potassium</mesh_term>
    <mesh_term>Maraviroc</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>ART Intensification: Maraviroc + Raltegravir</title>
          <description>ART Intensification (addition of raltegravir and maraviroc) to suppressive ART for 56 weeks</description>
        </group>
        <group group_id="P2">
          <title>Maraviroc + Raltegravir Plus DNA + HIV-rAd5 Vaccine</title>
          <description>ART Intensification (addition of raltegravir and maraviroc for 56 weeks) PLUS immunomodulation therapy with DNA prime vaccine (Weeks 8,12,16) + HIV-recombinant Ad5-based vaccine (Week 32)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ART Intensification: Maraviroc +Raltegravir</title>
          <description>ART Intensification (addition of raltegravir and maraviroc to suppressive ART for 56 weeks)</description>
        </group>
        <group group_id="B2">
          <title>Maraviroc + Raltegravir Plus DNA + HIV-rAd5 Vaccine</title>
          <description>ART Intensification (addition of raltegravir and maraviroc for 56 weeks) PLUS immunomodulation therapy with DNA prime vaccine (Weeks 8,12,16) + HIV-recombinant Ad5-based vaccine (Week 32)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
            <count group_id="B2" value="14"/>
            <count group_id="B3" value="28"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49" lower_limit="46" upper_limit="55"/>
                    <measurement group_id="B2" value="50" lower_limit="46" upper_limit="55"/>
                    <measurement group_id="B3" value="50" lower_limit="46" upper_limit="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CD4 cell count</title>
          <units>cells per mm^3</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="686" lower_limit="501" upper_limit="880"/>
                    <measurement group_id="B2" value="563" lower_limit="468" upper_limit="718"/>
                    <measurement group_id="B3" value="636" lower_limit="485" upper_limit="791"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Time on antiretroviral treatment (ART)</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13" lower_limit="8" upper_limit="19"/>
                    <measurement group_id="B2" value="13" lower_limit="6" upper_limit="19"/>
                    <measurement group_id="B3" value="13" lower_limit="8" upper_limit="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Adenovirus 5 antibody</title>
          <description>Serum Ad5 90% neutralization antibody titer</description>
          <units>titer</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18" lower_limit="12" upper_limit="68"/>
                    <measurement group_id="B2" value="12" lower_limit="12" upper_limit="38"/>
                    <measurement group_id="B3" value="12" lower_limit="12" upper_limit="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HIV DNA</title>
          <units>copies per 10^6 PBMC</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="97" lower_limit="47" upper_limit="352"/>
                    <measurement group_id="B2" value="228" lower_limit="98" upper_limit="383"/>
                    <measurement group_id="B3" value="170" lower_limit="60" upper_limit="361"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in HIV DNA in PBMCs at Week 56</title>
        <time_frame>56 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ART Intensification: Maraviroc +Raltegravir</title>
            <description>ART Intensification (addition of raltegravir and maraviroc to suppressive ART for 56 weeks)</description>
          </group>
          <group group_id="O2">
            <title>Maraviroc + Raltegravir Plus DNA + HIV-rAd5 Vaccine</title>
            <description>ART Intensification (addition of raltegravir and maraviroc for 56 weeks) PLUS immunomodulation therapy with DNA prime vaccine (Weeks 8,12,16) + HIV-recombinant Ad5-based vaccine (Week 32)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in HIV DNA in PBMCs at Week 56</title>
          <units>log^10 copies per 10^6 PBMCs</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="-0.29" upper_limit="0.16"/>
                    <measurement group_id="O2" value="0.04" lower_limit="-0.11" upper_limit="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in HIV DNA in Rectal Tissue at Week 56</title>
        <time_frame>Week 56</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Maraviroc + Raltegravir Intensification</title>
            <description>ART Intensification (addition of raltegravir and maraviroc to suppressive ART for 56 weeks)</description>
          </group>
          <group group_id="O2">
            <title>Maraviroc + Raltegravir Intens. Plus DNA + HIV-rAd5 Vaccine</title>
            <description>ART Intensification (addition of raltegravir and maraviroc for 56 weeks) PLUS immunomodulation therapy with DNA prime vaccine (Weeks 8,12,16) + HIV-recombinant Ad5-based vaccine (Week 32)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in HIV DNA in Rectal Tissue at Week 56</title>
          <units>log^10 copies per 10^6 cells</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.08" spread="0.27" lower_limit="-0.06" upper_limit="0.22"/>
                    <measurement group_id="O2" value="-0.02" spread="0.37" lower_limit="-0.02" upper_limit="0.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in CD4+ T Cell Count at Week 56</title>
        <time_frame>Week 56</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Maraviroc + Raltegravir Intensification</title>
            <description>ART Intensification (addition of raltegravir and maraviroc to suppressive ART for 56 weeks)</description>
          </group>
          <group group_id="O2">
            <title>Maraviroc + Raltegravir Intens. Plus DNA + HIV-rAd5 Vaccine</title>
            <description>ART Intensification (addition of raltegravir and maraviroc for 56 weeks) PLUS immunomodulation therapy with DNA prime vaccine (Weeks 8,12,16) + HIV-recombinant Ad5-based vaccine (Week 32)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in CD4+ T Cell Count at Week 56</title>
          <units>cells per mm^3</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1" lower_limit="-144" upper_limit="151"/>
                    <measurement group_id="O2" value="23" lower_limit="-100" upper_limit="114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HIV Specific T-cell Response to Env</title>
        <description>HIV-specific immunity: Interferon gamma ELISpot response to Env (clades A) at week 36 (one month after rAd5 boosting)</description>
        <time_frame>36 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Maraviroc + Raltegravir Intensification</title>
            <description>ART Intensification (addition of raltegravir and maraviroc to suppressive ART for 56 weeks)</description>
          </group>
          <group group_id="O2">
            <title>Maraviroc + Raltegravir Intens. Plus DNA + HIV-rAd5 Vaccine</title>
            <description>ART Intensification (addition of raltegravir and maraviroc for 56 weeks) PLUS immunomodulation therapy with DNA prime vaccine (Weeks 8,12,16) + HIV-recombinant Ad5-based vaccine (Week 32)</description>
          </group>
        </group_list>
        <measure>
          <title>HIV Specific T-cell Response to Env</title>
          <description>HIV-specific immunity: Interferon gamma ELISpot response to Env (clades A) at week 36 (one month after rAd5 boosting)</description>
          <units>response per 10^6 PBMCs</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28" spread="50"/>
                    <measurement group_id="O2" value="86" spread="235"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serious Adverse Events Attributed to Study Treatments</title>
        <description>Grade 3 or 4 serious adverse events related to study treatments (raltegravir, maraviroc, or HIV-recombinant Ad5-based vaccine)</description>
        <time_frame>56 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Maraviroc + Raltegravir Intensification</title>
            <description>ART Intensification (addition of raltegravir and maraviroc to suppressive ART for 56 weeks)</description>
          </group>
          <group group_id="O2">
            <title>Maraviroc + Raltegravir Intens. Plus DNA + HIV-rAd5 Vaccine</title>
            <description>ART Intensification (addition of raltegravir and maraviroc for 56 weeks) PLUS immunomodulation therapy with DNA prime vaccine (Weeks 8,12,16) + HIV-recombinant Ad5-based vaccine (Week 32)</description>
          </group>
        </group_list>
        <measure>
          <title>Serious Adverse Events Attributed to Study Treatments</title>
          <description>Grade 3 or 4 serious adverse events related to study treatments (raltegravir, maraviroc, or HIV-recombinant Ad5-based vaccine)</description>
          <units>serious adverse events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>56 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Maraviroc + Raltegravir Intensification</title>
          <description>ART Intensification (addition of raltegravir and maraviroc to suppressive ART for 56 weeks)</description>
        </group>
        <group group_id="E2">
          <title>Maraviroc + Raltegravir Intens. Plus DNA + HIV-rAd5 Vaccine</title>
          <description>ART Intensification (addition of raltegravir and maraviroc for 56 weeks) PLUS immunomodulation therapy with DNA prime vaccine (Weeks 8,12,16) + HIV-recombinant Ad5-based vaccine (Week 32)</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>acute coronary syndrome</sub_title>
                <description>Grade 3 left arm, neck and chest pain</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>creatine kinase</sub_title>
                <description>Grade 4 creatine kinase</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure</sub_title>
                <description>Grade 4 acute renal failure, Grade 4 creatinine</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>deep vein thrombosis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>Grade 3 deep vein thrombosis</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Baiba Berzins, MPH</name_or_title>
      <organization>Northwestern University</organization>
      <phone>312-695-5012</phone>
      <email>baiba@northwestern.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

